Adalta Ltd. · ASX:1AD
Adalta — Shareholder Meeting (November 2016)
11 slides from Adalta's shareholder meeting presentation, Nov 14, 2016
Slide 1: i-bodies – a new class of protein therapeutics to treat human disease
For personal use only i-bodies – a new class of protein therapeutics to treat human disease AGM November 2016 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) [email protected]
Slide 2: Disclaimer
Disclaimer For personal use only Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or in
Slide 3: Corporate and investment summary
Corporate and investment summary A drug discovery and development company For personal use only Capital structure focused on using its proprietary technology ASX code 1AD platform to generate a new class of protein Shares on issue* 101,037,617 therapeutics, known as i-bodies, for treating a Share pr
Slide 4: Recent updates
Recent updates For personal use only Manufacturing AD-114 – FujiFilm Diosynth Biotechnologies currently completing process development, formulation and manufacture of AdAlta’s lead i-body molecule AD-114 Orphan Drug Designation – Additional pre-clinical data for AD-114 required by FDA – Allowing for
Slide 5: Financials
Financials For personal use only The Company remains in a solid cash position with ~$10 million cash in the bank as at 30 September 2016 – Closed IPO in August 2016, with oversubscribed offer, raising $10m to advance the lead i-body candidate AD-114 to the clinic for the treatment of IPF – Receipt o
Slide 6: AD-114 development: key milestones
AD-114 development: key milestones For personal use only CY2016 CY2017 CY2018 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Partnering of lead Manufacturing AD-114 candidate based on other Toxicology studies benchmark deals Orphan designation Phase I Publication of data Other fibrosis indications BD and partnerships 6
Slide 7: Expected newsflow next months
Expected newsflow next 12 months For personal use only Q3 2016 ü Commence manufacturing of material for toxicology testing with FujiFilm Diosynth Biotechnologies Q4 2016 Additional AD-114 IPF fibrosis data Hypertrophic scarring animal results for AD-114 Completion of evaluation of AD-114 with IPF cl
Slide 8: AdAlta business model – strategy to create value
AdAlta business model – strategy to create value For personal use only Pharma & biotech partnerships Revenues: Upfronts, i-body FTEs, milestones & royalties i-bodies new technology drug class platform and Potential in multiple library In-house disease indications Licence to pipeline of pharma drug R
Slide 9: Market benchmarks
Market benchmarks For personal use only Fibrosis lead AD-114 Sep-15 acquired by Roche Aug-15 acquired by BMS Nov-14 acquired by BMS $105m + $475m milestones $150m + $1.25b milestones $444m phase I asset phase IIa asset phase I asset Next gen antibodies April-16 with Abbvie Dec -15 with Roche Nov-15
Slide 10: Management and Board in place to deliver strategy
Management and Board in Internationally recognised SAB with proven track place to deliver strategy For personal use only record of drug development Sam Cobb: Founding Dr John Chiplin: David McGibney: pre-clinical CEO and Director Independent Director and clinical advisor Extensive experience in rais
Slide 11: AdAlta investment summary
AdAlta investment summary For personal use only Powerful proprietary technology platform to develop a pipeline of i-bodies for the treatment of a wide range of human diseases Initial focus on treating Idiopathic Pulmonary Fibrosis and other fibrotic diseases - high unmet clinical need Advanced lead